Condition
Advanced Leiomyosarcoma
Total Trials
5
Recruiting
2
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 1 (4)
Trial Status
Recruiting2
Enrolling By Invitation1
Active Not Recruiting1
Terminated1
Clinical Trials (5)
Showing 5 of 5 trials
NCT06498648Phase 1Recruiting
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
NCT05099666Phase 1Active Not Recruiting
Lurbinectedin + Doxorubicin In Leiomyosarcoma
NCT07405346Not ApplicableEnrolling By InvitationPrimary
A Trial for Advanced Leiomyosarcoma With Human Organoid-guided Personalized Efficacy
NCT06957431Phase 1RecruitingPrimary
Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
NCT03670069Phase 1Terminated
Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
Showing all 5 trials